New treatments for lung disease in cystic fibrosis
Molecular Therapies for Cystic Fibrosis Lung Disease
This study is looking for new ways to help people with cystic fibrosis breathe better by fixing the genes that cause lung problems and using special treatments to improve lung function.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-10892132 on NIH RePORTER |
What this research studies
This research focuses on developing innovative molecular therapies to treat lung disease caused by cystic fibrosis (CF), a genetic condition that leads to severe respiratory issues. The team aims to enhance current treatment methods by exploring gene repair techniques and the use of small molecules to improve lung function. By utilizing advanced in vitro and animal models, the researchers will investigate how to restore the function of the CFTR protein, which is crucial for lung health. The project includes targeted editing of genetic mutations and understanding how certain compounds can aid in lung function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis, particularly those with specific genetic mutations that have not responded to existing treatments.
Not a fit: Patients with cystic fibrosis who have already benefited from current CFTR modulator therapies may not receive additional benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve lung function and quality of life for individuals with cystic fibrosis.
How similar studies have performed: Previous research has shown promise in using gene editing techniques for genetic disorders, indicating potential success for this novel approach in cystic fibrosis.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Mccray, Paul B — University of Iowa
- Study coordinator: Mccray, Paul B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.